REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

-Second Phase II trial to evaluate RGX-314 using the SCS Microinjector® -Initial data from ALTITUDE expected in 2021 ROCKVILLE, Md. , Dec. 10, 2020 /PRNewswire/ —  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential

No Comments

Comments are closed.